Free Trial
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:GHRS

GH Research Q3 2025 Earnings Report

GH Research logo
$21.28 -0.41 (-1.89%)
Closing price 04:00 PM Eastern
Extended Trading
$21.09 -0.19 (-0.89%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

GH Research EPS Results

Actual EPS
-$0.23
Consensus EPS
-$0.23
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

GH Research Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

GH Research Announcement Details

Quarter
Q3 2025
Date
11/6/2025
Time
Before Market Opens
Conference Call Date
Wednesday, November 5, 2025
Conference Call Time
6:00PM ET

Upcoming Earnings

GH Research's Q1 2026 earnings is estimated for Thursday, May 7, 2026, based on past reporting schedules

Conference Call Resources

Powered by Quartr

Earnings Documents

GH Research's Q3 2025 Earnings ReleaseEarnings Release
(6-K)

GH Research Earnings Headlines

GH Research Raises $111 Million in Completed Share Offering to Fund Depression Pipeline
April 30, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/gh-research-raises-111-million-in-completed-share-offering-to-fund-depression-pipeline?utm_source=marketbeat.com&utm_medium=referral
GH Research Announces Pricing of $117.5 Million Underwritten Offering
April 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/29/3283701/0/en/gh-research-announces-pricing-of-117-5-million-underwritten-offering.html
I was right about SpaceX
Jeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,000%. Now he says SpaceX is shaping up to be the biggest IPO of the decade - and three key milestones just confirmed it. In the past 21 days: SpaceX crossed 10,000 active satellites, Elon filed confidential IPO paperwork with the SEC, and another rocket launched 25 more satellites. Two-thirds of every satellite in orbit now belongs to one company. The public filing could drop any day.tc pixel
May 5 at 1:00 AM  |  Brownstone Research (Ad)
GH Research: WH Decision On Psychedelics To Treat Depression Makes Bull Case
April 20, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4892025-gh-research-wh-decision-on-psychedelics-to-treat-depression-makes-bull-case
GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental Illness
April 20, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/20/3277100/0/en/gh-research-welcomes-white-house-executive-order-to-accelerate-medical-treatments-for-serious-mental-illness.html
Here's Why We're Not At All Concerned With GH Research's (NASDAQ:GHRS) Cash Burn Situation
April 4, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/heres-why-were-not-concerned-140601844.html
See More GH Research Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like GH Research? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GH Research and other key companies, straight to your email.

About GH Research

GH Research (NASDAQ:GHRS) Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression. An additional preclinical candidate, GH002, is being developed for broader indications including anxiety, cognitive impairment and substance use disorders. GH Research employs a proprietary platform to optimize dosing, formulation delivery and real-time patient monitoring.

Founded in 2017 by biotechnology entrepreneur Christian Angermayer, GH Research operates research facilities in Ireland and maintains collaborations with academic institutions and contract research organizations across Europe and North America. The executive leadership team combines expertise in psychiatry, neuroscience and drug development to advance the company’s pipeline.

GH Research engages with regulatory authorities in multiple jurisdictions as it plans to initiate later-stage clinical trials and pursue strategic partnerships. The company’s goal is to bring innovative, psychedelic-derived therapeutics to patients worldwide who face debilitating psychiatric conditions.

View GH Research Profile
Earnings Tools